Chemotherapy News and Research

Latest Chemotherapy News and Research

Hearing loss with radiotherapy for head and neck tumors

Radiotherapy for head and neck tumors has permanent, progressive, and dose-dependent effects on patients’ hearing, report researchers.

15 Jan 2013

Emergency departments drained of resources for elderly

Plans are needed to accommodate the growing demands on emergency departments to provide suitable care for older individuals in the USA, say researchers.

15 Jan 2013

Beta blocker use linked to NSCLC patient survival

Beta blockers may boost survival in patients undergoing definitive radiotherapy for non-small-cell lung cancer, suggests research published in the Annals of Oncology.

14 Jan 2013

Results from Morphotek’s farletuzumab Phase III combination study on ovarian cancer

Morphotek Inc., a wholly-owned subsidiary of Eisai Inc., announced today top-line results from a Phase III study of its investigational agent farletuzumab (MORAb-003) in combination with carboplatin and a taxane in patients with platinum-sensitive epithelial ovarian cancer in first relapse.

11 Jan 2013

New guidelines to help fast track radiation oncology drug development

Researchers from the translational research program of the National Cancer Institute and the Radiation Therapy Oncology Therapy Group have developed new guidelines to help fast track the clinical development of targeted cancer drugs in combination with radiation therapy.

11 Jan 2013

Research: Smaller radiation fields can effectively treat aggressive brain tumors

New research from Wake Forest Baptist Medical Center shows that patients suffering from aggressive brain tumors can be effectively treated with smaller radiation fields to spare the rest of the brain and preserve cognition.

11 Jan 2013

Mutation that causes sickle cell anemia may offer new way to treat drug-resistant cancers

The genetic mutation that causes sickle cell anemia also turns red blood cells into potent tumor killers and may offer a new way to treat cancers that are resistant to existing treatments, according to research published January 9, 2013 in the open access journal PLOS ONE by David S. Terman of Jenomic Research Institute and colleagues from Duke University and other institutions.

10 Jan 2013

Combination of pazopanib and paclitaxel shows promise in slowing anaplastic thyroid cancer

A combination of the drugs pazopanib and paclitaxel shows promise in slowing anaplastic thyroid cancer (ATC), according to a Mayo Clinic-led study published in the journal Science Translational Medicine.

9 Jan 2013

Key link between stem cell factors that fuel ovarian cancer's growth and patient prognosis

Researchers at Yale School of Medicine have identified a key link between stem cell factors that fuel ovarian cancer's growth and patient prognosis. The study, which paves the way for developing novel targeted ovarian cancer therapies, is published online in the current issue of Cell Cycle.

9 Jan 2013

Seven scientists named 2013 recipients of Damon Runyon-Rachleff Innovation Award

The Damon Runyon Cancer Research Foundation announced that seven scientists with novel approaches to fighting cancer have been named 2013 recipients of the Damon Runyon-Rachleff Innovation Award.

8 Jan 2013

Consumers' perceptions of medical prices can be faulty

Despite advocates' push for more transparency in medical pricing, consumers may draw the wrong message when they know what a health service or good costs.

4 Jan 2013

Markey practitioner receives Lexington Cancer Foundation grant to continue JSJ program

The University of Kentucky Markey Cancer Center's Jennifer Bradley has received funding from the Lexington Cancer Foundation to continue the Jin Shin Jyutsu program in 2013.

4 Jan 2013

Algorithms designed to find patients with recurrent cancer within databases do not work

In order to study the effectiveness or cost effectiveness of treatments for recurrent cancer, you first have to discover the patients in medical databases who have recurrent cancer. Generally studies do this with billing or treatment codes - certain codes should identify who does and does not have recurrent cancer. A recent study published in the journal Medical Care shows that the commonly used data determinants of recurrent cancer may be misidentifying patients and potentially leading researchers astray.

4 Jan 2013

Mayo Clinic researchers identify new target to improve treatment of pancreatic cancer

Researchers at Mayo Clinic in Florida have identified a new target to improve treatment of pancreatic ductal adenocarcinoma cancer, which accounts for more than 95 percent of pancreatic cancer cases. This fast-growing, often lethal cancer is resistant to conventional chemotherapy.

4 Jan 2013

Many male cancer patients missing out on appropriate fertility advice

Pioneering research presented at the Fertility 2013 conference today shows that a large proportion of male cancer patients are missing out on appropriate fertility advice.

4 Jan 2013

Partin Tables to predict prostate cancer spread now updated

Prostate cancer experts at Johns Hopkins have developed an updated version of the Partin Tables, a tool to help men diagnosed with prostate cancer and their doctors to better assess their chance of a surgical cure. The updated tool, based on a study of more than 5,600 men treated at The Johns Hopkins Hospital from 2006 to 2011, is published in the Jan. 3 issue of the British Journal of Urology International.

3 Jan 2013

Trovagene, MD Anderson partner to detect transrenal BRAF mutations in metastatic cancers

Trovagene, Inc., a developer of transrenal molecular diagnostics, announced that it has entered into a clinical collaboration with The University of Texas MD Anderson Cancer Center to detect transrenal BRAF mutations in the urine of patients with advanced or metastatic cancers.

3 Jan 2013

$Bayer, Onyx announce data from Nexavar Phase 3 trial on RAI-refractory differentiated thyroid cancer$

Bayer, Onyx announce data from Nexavar Phase 3 trial on RAI-refractory differentiated thyroid cancer

Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. today announced that a Phase 3 trial of Nexavar (sorafenib) tablets in patients with locally advanced or metastatic radioactive iodine-refractory (RAI) differentiated thyroid cancer has met its primary endpoint of a statistically significant improvement of progression-free survival.

3 Jan 2013

Aeterna Zentaris reaches SPA agreement with FDA for AEZS-108 Phase 3 trial in endometrial cancer

Aeterna Zentaris Inc. today announced that it has reached an agreement with the U.S. Food and Drug Administration ("FDA") on a Special Protocol Assessment ("SPA") for an upcoming Phase 3 registration trial in endometrial cancer with its doxorubicin peptide conjugate, AEZS-108. The SPA agreement states that the proposed trial protocol design, clinical endpoints and planned analyses are acceptable to the FDA to support a regulatory submission.

29 Dec 2012

Trovagene adds Duke University Health System to worldwide licensees of NPM1 marker for AML

Trovagene, Inc., a developer of transrenal molecular diagnostics, announced it has granted Duke University and Duke University Health Systems a non-exclusive license to incorporate nucleophosmin protein (NPM1) into research and clinical testing services for acute myelogenous leukemia (AML).

27 Dec 2012

Chemotherapy News and Research

Latest Chemotherapy News and Research

Hearing loss with radiotherapy for head and neck tumors

Emergency departments drained of resources for elderly

Beta blocker use linked to NSCLC patient survival

Results from Morphotek’s farletuzumab Phase III combination study on ovarian cancer

New guidelines to help fast track radiation oncology drug development

Research: Smaller radiation fields can effectively treat aggressive brain tumors

Mutation that causes sickle cell anemia may offer new way to treat drug-resistant cancers

Combination of pazopanib and paclitaxel shows promise in slowing anaplastic thyroid cancer

Key link between stem cell factors that fuel ovarian cancer's growth and patient prognosis

Seven scientists named 2013 recipients of Damon Runyon-Rachleff Innovation Award

Consumers' perceptions of medical prices can be faulty

Markey practitioner receives Lexington Cancer Foundation grant to continue JSJ program

Algorithms designed to find patients with recurrent cancer within databases do not work

Mayo Clinic researchers identify new target to improve treatment of pancreatic cancer

Many male cancer patients missing out on appropriate fertility advice

Partin Tables to predict prostate cancer spread now updated

Trovagene, MD Anderson partner to detect transrenal BRAF mutations in metastatic cancers

Bayer, Onyx announce data from Nexavar Phase 3 trial on RAI-refractory differentiated thyroid cancer

Aeterna Zentaris reaches SPA agreement with FDA for AEZS-108 Phase 3 trial in endometrial cancer

Trovagene adds Duke University Health System to worldwide licensees of NPM1 marker for AML

Cancer Research - Second Edition eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Chemotherapy News and Research

Latest Chemotherapy News and Research

Cancer Research - Second Edition eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Newsletters you may be interested in